Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DES restenosis rates on the rise?

This article was originally published in The Gray Sheet

Executive Summary

"As sirolimus-coated stents move into general use, it is likely that the rate of restenosis will be higher than that shown in the SIRIUS trial," Andrew Marks, MD, states in Oct. 2 New England Journal of Medicine editorial. The article accompanies publication of the Johnson & Johnson/Cordis Cypher sirolimus-eluting stent study, in which the device was associated with an 8.9% six-month binary restenosis rate. Marks cites a 121-patient series by Pero Lemos, MD, Erasmus Medical Center, Rotterdam, showing 16% restenosis (1"The Gray Sheet" Sept. 22, 2003, p. 4)...

You may also be interested in...



Cordis Counters TAXUS IV With “New SIRIUS,” Critiques Angiographic Data

The revascularization rates associated with Boston Scientific's Taxus paclitaxel-eluting stent in TAXUS IV are "artificially" depressed by the relatively low rate of angiographic follow-up in the trial, according to rival Johnson & Johnson/Cordis

Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA

AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.

World-First Nod For Yuhan's Lung Cancer Drug, In Korea

The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel